Loading stock data…
C4 Therapeutics (CCCC)
$4.35+0.09 (+2.11%)
After Hours$4.35+0.00 (+0.00%)· Last close Jun 29
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
C4 Therapeutics, Inc. in the Healthcare sector is trading at $4.35 with a market capitalization of $406M. Wall Street consensus targets $13.33 (6 analysts), implying a +206.5% move over the next 12 months. The stock is currently near its 52-week high of $4.60, remaining 60.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +206.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.15M↓ | $11.02M↓ | $11.23M↑ | $6.46M↓ | $7.24M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$27.79M↓ | -$23.14M↑ | -$23.68M↑ | -$28.50M↑ | -$29.16M |
| Net Income | -$25.13M↓ | -$20.49M↑ | -$32.17M↓ | -$26.02M↑ | -$26.32M |
Peer Comparison
JNJUNHPFE
Fundamentals
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$406.33M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-44.31%
Volume
Today's trading volume
3.11M
Recent News
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D
C4 Therapeutics (CCCC) said Phase 1 data to be presented at the European Hematology Association 2026
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?
Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
C4 Therapeutics, Inc. (NASDAQ:CCCC) Just Reported And Analysts Have Been Lifting Their Price Targets
C4 Therapeutics, Inc. ( NASDAQ:CCCC ) defied analyst predictions to release its first-quarter results, which were ahead...